Choroideremia Clinical Trials 2024

Choroideremia Clinical Trials 2024

Choroideremia research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in choroideremia clinical trials today.

Choroideremia Clinical Trials

Here are the 0 most popular medical studies for choroideremia

Popular filter options for choroideremia trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to choroideremia

What are the top hospitals conducting choroideremia research?

In the realm of clinical trials for choroideremia, several hospitals are making significant strides in research and treatment options. The Retina Foundation of the Southwest, located in Dallas, has emerged as a leader with two ongoing choroideremia trials and a total of three conducted studies. This foundation embarked on its first choroideremia trial in 2016, demonstrating its commitment to exploring innovative therapies for this rare genetic disorder that affects vision.

The Moran Eye Center at the University of Utah in Salt Lake City is also contributing to advancements in choroideremia research. With one active trial currently underway and two completed trials under their belt thus far, this renowned institute has been dedicated to studying the condition since 2016 when it initiated its inaugural clinical trial.

Meanwhile, other notable research sites have joined the effort to combat choroideremia. A site based out of Gainesville has an ongoing clinical trial with hopes of improving understanding and treatment options for patients affected by this disease. In Miami, another research site is working diligently on their first recorded trial back in 2015; they currently have one active trial along with four previously conducted ones aimed at tackling choroideremia head-on. Additionally joining these efforts is a research site situated in Cincinnati which entered into chorus investigating novel approaches toward managing this ailment from around2017 onwards; they now boast both an active clinical experiment as well as thee successfully completed investigations into possible treatments.

These hospitals and institutes are beacons of hope for those living with or impacted by choroideremia - a condition characterized by progressive vision loss due to degeneration within specific cells that support retinal function. Through their dedication and collaborative efforts, researchers aim not only to develop effective therapies but also provide improved quality of life for individuals battling this rare eye disorder.

Which are the best cities for choroideremia clinical trials?

When it comes to choroideremia clinical trials, several cities have emerged as key players in the research landscape. Dallas, Texas, leads the way with three active trials focused on studying BIIB111 and other potential treatments. Additionally, Gainesville, Florida; Miami, Florida; Cincinnati, Ohio; and Portland, Oregon each offer two active trials examining the efficacy of BIIB111 and other interventions for choroideremia. These cities provide individuals affected by this condition with access to ongoing research that may lead to groundbreaking advancements in treatment and management.

Which are the top treatments for choroideremia being explored in clinical trials?

In the realm of choroideremia clinical trials, two treatments have risen to prominence. First on the list is 4D-110, a promising option currently under investigation in one active trial. With its recent listing in 2020, it holds tremendous potential for patients with this condition. Also gaining attention is BIIB111, which made its debut in 2017 and has since been involved in three all-time choroideremia trials. These innovative therapies offer hope for individuals battling choroideremia and signify significant progress in the search for effective treatments.

What are the most recent clinical trials for choroideremia?

Exciting progress has been made in the field of choroideremia, with recent clinical trials offering hope for those affected by this condition. One notable trial is investigating the potential of 4D-110 as a treatment option. In its Phase 1 stage, this therapy aims to address the underlying causes of choroideremia and potentially halt disease progression. Additionally, BIIB111 is undergoing Phase 3 testing to assess its efficacy in treating individuals with choroideremia. These advancements bring optimism for improved management and outcomes for patients living with this inherited retinal disorder.

What choroideremia clinical trials were recently completed?

A recent milestone in the field of choroideremia research was reached when Biogen successfully completed a clinical trial for BIIB111 in November 2017. This trial, sponsored by Biogen, represents an important step towards advancing our understanding and treatment options for this inherited retinal disorder. The completion of this trial showcases the commitment of researchers and provides hope for individuals affected by choroideremia as we continue to make progress in finding effective therapies.